{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T07:32:21Z","timestamp":1770363141651,"version":"3.49.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-025-06689-2","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T03:26:29Z","timestamp":1766028389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tolvaptan pharmacokinetics and pharmacodynamics in adolescents with autosomal dominant polycystic kidney disease"],"prefix":"10.1007","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7725-9385","authenticated-orcid":false,"given":"Susan E.","family":"Shoaf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Sikes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"25","key":"6689_CR1","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/nejmoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E et al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367(25):2407\u20132418. https:\/\/doi.org\/10.1056\/nejmoa1205511","journal-title":"N Engl J Med"},{"issue":"20","key":"6689_CR2","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/nejmoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G et al (2017) Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 377(20):1930\u20131942. https:\/\/doi.org\/10.1056\/nejmoa1710030","journal-title":"N Engl J Med"},{"issue":"7","key":"6689_CR3","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00431-019-03384-x","volume":"178","author":"F Schaefer","year":"2019","unstructured":"Schaefer F, Mekahli D, Emma F, Gilbert RD, Bockenhauer D, Cadnapaphornchai MA et al (2019) Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial. Eur J Pediatr 178(7):1013\u20131021. https:\/\/doi.org\/10.1007\/s00431-019-03384-x","journal-title":"Eur J Pediatr"},{"issue":"1","key":"6689_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2215\/cjn.0000000000000022","volume":"18","author":"D Mekahli","year":"2023","unstructured":"Mekahli D, Guay-Woodford LM, Cadnapaphornchai MA, Greenbaum LA, Litwin M, Seeman T et al (2023) Tolvaptan for children and adolescents with autosomal dominant polycystic kidney disease: randomized controlled trial. Clin J Am Soc Nephrol 18(1):36\u201346. https:\/\/doi.org\/10.2215\/cjn.0000000000000022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 1","key":"6689_CR5","doi-asserted-by":"publisher","first-page":"i644","DOI":"10.1093\/ndt\/gfad063c_3034","volume":"38","author":"D Mekahli","year":"2023","unstructured":"Mekahli D, Guay-Woodford L, Cadnapaphornchai M, Greenbaum LA, Litwin M, Seeman T et al (2023) Phase 3 trial of tolvaptan in pediatric autosomal dominant polycystic kidney disease (ADPKD): two years of data from an open-label extension. Nephrol Dial Transplant 38(Suppl 1):i644\u2013i646. https:\/\/doi.org\/10.1093\/ndt\/gfad063c_3034","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"6689_CR6","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/jcph.880","volume":"57","author":"SE Shoaf","year":"2017","unstructured":"Shoaf SE, Chapman AB, Torres VE, Ouyang J, Czerwiec FS (2017) Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: phase 2 trials for dose selection in the pivotal phase 3 trial. J Clin Pharmacol 57(7):906\u2013917. https:\/\/doi.org\/10.1002\/jcph.880","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"6689_CR7","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1177\/0091270007307877","volume":"47","author":"SE Shoaf","year":"2007","unstructured":"Shoaf SE, Wang Z, Bricmont P, Mallikaarjun S (2007) Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J Clin Pharmacol 47(12):1498\u20131507. https:\/\/doi.org\/10.1177\/0091270007307877","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"6689_CR8","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/jcph.1370","volume":"59","author":"S Lanke","year":"2019","unstructured":"Lanke S, Shoaf SE (2019) Population pharmacokinetic analyses and model validation of tolvaptan in subjects with autosomal dominant polycystic kidney disease. J Clin Pharmacol 59(5):763\u2013770. https:\/\/doi.org\/10.1002\/jcph.1370","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"6689_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5414\/cp201621","volume":"50","author":"SE Shoaf","year":"2012","unstructured":"Shoaf SE, Bricmont P, Mallikaarjun S (2012) Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects. Int J Clin Pharmacol Ther 50(2):150\u2013156. https:\/\/doi.org\/10.5414\/cp201621","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"6689_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2125.2011.04114.x","volume":"73","author":"SE Shoaf","year":"2012","unstructured":"Shoaf SE, Bricmont P, Mallikaarjun S (2012) Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. Br J Clin Pharmacol 73(4):579\u2013587. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04114.x","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06689-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-025-06689-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06689-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T02:31:15Z","timestamp":1770258675000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-025-06689-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["6689"],"URL":"https:\/\/doi.org\/10.1007\/s00431-025-06689-2","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Compliance with ethical standards in this trial, including the Declaration of Helsinki, was previously reported by Schaefer et al.:\n                      Eur J Pediatr\n                      2019;178:1013\u201321. Written informed consent was obtained from a parent\/guardian or legally acceptable representative, and the trial participants provided age-appropriate informed assent. The study was authorized by the Independent Ethics Committee of UZ Leuven (Leuven, Belgium), the institution of the Coordinating Investigator, and by those of the participating institutions at each study site.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SES and KS are employees of Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, United States.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}